https://scholars.lib.ntu.edu.tw/handle/123456789/537506
標題: | Clinical implications of SOCS1 methylation in myelodysplastic syndrome | 作者: | SHANG-JU WU MING YAO WEN-CHIEN CHOU JIH-LUH TANG Chen, Chien-Yuan BOR-SHENG KO Huang S.-Y. WOEI TSAY YAO-CHANG CHEN MING-CHING SHEN Wang C.-H. Yeh Y.-C. HWEI-FANG TIEN |
公開日期: | 2006 | 卷: | 135 | 期: | 3 | 起(迄)頁: | 317-323 | 來源出版物: | British Journal of Haematology | 摘要: | The suppressor of cytokine signalling-1 (SOCS1) protein is a tumour suppressor. Hypermethylation of SOCS1 gene, resulting in transcriptional silencing, is suggested to play an important role in cancer development. We sought to characterise SOCS1 methylation in primary myelodysplastic syndrome (MDS) and clarify its clinical implications. The methylation status of SOCS1 was analysed by methylation-specific polymerase chain reaction in 114 patients with primary MDS and serial studies were performed in 29 of them. SOCS1 methylation occurred in 54 patients (47.4%), and was more frequent in patients with high-risk MDS than in those with low-risk (52.6% vs. 25.8%, P = 0.011). SOCS1 methylation was closely associated with NRAS mutation (P = 0.010) and inversely associated with good-risk karyotype (P = 0.021). With a median follow-up of 17 months (range: 1-231 months), two patients acquired SOCS1 methylation during disease progression. In two patients, SOCS1 methylation present at diagnosis, disappeared after haematopoietic stem cell transplantation. Patients with SOCS1 methylation had a higher cumulative risk of leukaemic transformation than those without (55.8% vs. 27.7% at 3 years, P = 0.004). This difference remained significant within the subgroup of patients with high-risk MDS (67.3% vs. 45.1% at 3 years, P = 0.045). This is the first report to demonstrate the clinical relevance of SOCS1 methylation in MDS. It may play an important role in the pathogenesis of MDS, especially among patients with high-risk subtypes. ? 2006 The Authors. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33749244450&doi=10.1111%2fj.1365-2141.2006.06293.x&partnerID=40&md5=b86379a7ef9bb8e73e274c378fbfbffc https://scholars.lib.ntu.edu.tw/handle/123456789/537506 http://ntur.lib.ntu.edu.tw//handle/246246/225845 |
ISSN: | 0007-1048 | DOI: | 10.1111/j.1365-2141.2006.06293.x | SDG/關鍵字: | suppressor of cytokine signaling 1; adolescent; adult; aged; article; disease association; disease course; female; follow up; gene mutation; hematopoietic stem cell transplantation; human; karyotype; major clinical study; male; myelodysplastic syndrome; pathogenesis; polymerase chain reaction; priority journal; protein methylation; school child; Adolescent; Adult; Aged; Aged, 80 and over; Child; Chromosome Aberrations; Disease Progression; Female; Genes, ras; Humans; Karyotyping; Leukemia; Male; Methylation; Middle Aged; Mutation; Myelodysplastic Syndromes; Polymerase Chain Reaction; Prognosis; Risk Factors; Suppressor of Cytokine Signaling Proteins |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。